<DOC>
	<DOC>NCT01657162</DOC>
	<brief_summary>The purpose of this study is to provide 24 months of standard of care data on subjects previously enrolled in study BA058-05-003.</brief_summary>
	<brief_title>Twenty Four Month Extension Study of BA058-05-003</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>1. The subject was enrolled, randomized to either the BA058 (abaloparatide) or placebo arm, and successfully completed Study BA05805003. 1. Were withdrawn from Study BA05805003 for any reason. 2. Experienced a treatmentrelated SAE during Study BA05805003.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>BA058</keyword>
	<keyword>Abaloparatide-SC</keyword>
	<keyword>abaloparatide</keyword>
	<keyword>ACTIVExtend</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>fracture</keyword>
	<keyword>bone loss</keyword>
</DOC>